Literature DB >> 415379

Teratogenic effects of ribavirin on hamster and rat embryos.

V H Ferm, C Willhite, L Kilham.   

Abstract

Ribavirin, a synthetic nucleoside with marked antiviral activity, induced developmental malformations when administered to pregnant hamsters by oral, intraperitoneal or intravenous routes. Abnormalities of the limbs, eyes and brain were the most common defects found in the hamster. Higher doses (about 10 x) were required to induce anomalies in rat embryos and the malformations were generally restricted to the head region. In both rats and hamsters oral administration of the drug seemed to be more teratogenic than administration by other routes suggesting that metabolism of ribavirin in the maternal gastro-intestinal tract and/or liver may change it into its active form.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 415379     DOI: 10.1002/tera.1420170117

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  21 in total

1.  The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.

Authors:  Kathleen B Schwarz; Regino P Gonzalez-Peralta; Karen F Murray; Jean P Molleston; Barbara A Haber; Maureen M Jonas; Philip Rosenthal; Parvathi Mohan; William F Balistreri; Michael R Narkewicz; Lesley Smith; Steven J Lobritto; Stephen Rossi; Alexandra Valsamakis; Zachary Goodman; Patricia R Robuck; Bruce A Barton
Journal:  Gastroenterology       Date:  2010-10-28       Impact factor: 22.682

Review 2.  Paternal use of ribavirin-interferon alpha 2B combination therapy before conception.

Authors:  Nobuko Taguchi; Shinya Ito
Journal:  Can Fam Physician       Date:  2005-12       Impact factor: 3.275

3.  Ribavirin: is there a risk to hospital personnel? Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1991-02-01       Impact factor: 8.262

Review 4.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

5.  Gross-structural defects in rats after acyclovir application on day 10 of gestation.

Authors:  I Chahoud; R Stahlmann; G Bochert; I Dillmann; D Neubert
Journal:  Arch Toxicol       Date:  1988-08       Impact factor: 5.153

Review 6.  Severe acute respiratory syndrome (SARS) in neonates and children.

Authors:  A M Li; P C Ng
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-11       Impact factor: 5.747

7.  Spontaneous Clearance of Hepatitis C Virus during Pregnancy.

Authors:  Penelope Clohessy; Suzanne Polis; Jeffrey Post
Journal:  Obstet Med       Date:  2013-03-01

8.  Inhibition of cadmium teratogenesis by a mercaptoacrylic acid (MFA).

Authors:  V H Ferm; D P Hanlon
Journal:  Experientia       Date:  1987-02-15

9.  Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.

Authors:  Karen F Murray; James R Rodrigue; Regino P González-Peralta; John Shepherd; Bruce A Barton; Patricia R Robuck; Kathleen B Schwarz
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

10.  Synthesis of 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus.

Authors:  Dong-Hoon Chung; Sidath C Kumarapperuma; Yanjie Sun; Qianjun Li; Yong-Kyu Chu; Jeffrey B Arterburn; William B Parker; Jeffrey Smith; Kristin Spik; Harish N Ramanathan; Connie S Schmaljohn; Colleen B Jonsson
Journal:  Antiviral Res       Date:  2008-03-17       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.